MAP2K1 and cancer: To examine if the two classes of the MEK mutations differentially affect ERK signaling processes, we established HEK293 cells stably expressing HA-MEK1, or a representative disease-associated MEK mutant (RASopathies, F53S; Cancer, K57N) (Supplementary Fig. 5a).